MSI 130
Latest Information Update: 08 Aug 2007
Price :
$50 *
At a glance
- Originator Genaera Corporation
- Class Antineoplastics
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 30 Jul 1998 No-Development-Reported for Malignant melanoma in USA (Unknown route)
- 15 Feb 1995 Preclinical development for Malignant melanoma in USA (Unknown route)